MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125.
MCT-125 is the company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).
In an earlier Phase IIa study, MCT-125 was tested on 138 patients suffering from PMSF. MCT-125 was shown to be effective within 4 weeks of administration, was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type (primary progressive, secondary progressive and relapsing-remitting).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2354